Sascha Weggen

Summary

Affiliation: Heinrich Heine University
Country: Germany

Publications

  1. ncbi request reprint Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds
    Eva Czirr
    Emmy Noether Research Group, Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg University Mainz, Mainz, Germany
    Neurodegener Dis 3:298-304. 2006
  2. ncbi request reprint NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?
    Sascha Weggen
    Molecular Neuropathology Group, Department of Neuropathology, Heinrich Heine University, D 40225 Dusseldorf, Germany
    Trends Pharmacol Sci 28:536-43. 2007
  3. pmc LRP1 is critical for the surface distribution and internalization of the NR2B NMDA receptor subtype
    Wladislaw Maier
    University Medical Center of the Johannes Gutenberg University of Mainz Institute of Pathobiochemistry, Duesbergweg 6, Mainz 55099, Germany
    Mol Neurodegener 8:25. 2013
  4. pmc Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease
    Sascha Weggen
    Department of Neuropathology, Heinrich Heine University, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    Alzheimers Res Ther 4:9. 2012
  5. ncbi request reprint Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening
    Heiko Zettl
    Department of Neuropathology, Heinrich Heine University, D 40225 Duesseldorf, Germany
    ACS Chem Biol 7:1488-95. 2012
  6. doi request reprint Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase
    Eva Czirr
    Molecular Neuropathology Group, Department of Neuropathology, Heinrich Heine University, D 40225 Duesseldorf, Germany
    J Biol Chem 283:17049-54. 2008
  7. doi request reprint Nonsteroidal anti-inflammatory drugs and ectodomain shedding of the amyloid precursor protein
    Stefanie Leuchtenberger
    Department of Neuropathology, Heinrich Heine University, Dusseldorf, Germany
    Neurodegener Dis 6:1-8. 2009
  8. ncbi request reprint Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations
    Eva Czirr
    Emmy Noether Research Group, Mainz, Germany
    J Biol Chem 282:24504-13. 2007
  9. ncbi request reprint Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond
    Stefanie Leuchtenberger
    Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
    Curr Pharm Des 12:4337-55. 2006
  10. ncbi request reprint Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production
    Thomas Kukar
    Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    Nat Med 11:545-50. 2005

Collaborators

  • Dirk Beher
  • Gisbert Schneider
  • Thomas L Kukar
  • Edward Koo
  • Boris Schmidt
  • Pritam Das
  • Jens Wiltfang
  • T E Golde
  • Stefanie Leuchtenberger
  • Eva Czirr
  • Claus U Pietrzik
  • Karlheinz Baumann
  • Sarah A Sagi
  • Wladislaw Maier
  • Heiko Zettl
  • Julia Ness
  • Hermann Esselmann
  • Rajeshwar Narlawar
  • Elaine Waldron
  • Thomas B Ladd
  • Jason L Eriksen
  • Ulrich Schmitt
  • Anton Roebroek
  • Mariola Bednorz
  • Sabrina Meister
  • Thorsten Jumpertz
  • Arman Saric
  • Volker Hähnke
  • Bruno Bulic
  • Stefan F Lichtenthaler
  • Juan Maler
  • Klaudia Brix
  • Nirupa Nadella
  • Catherine Heilig
  • Robert Schubenel
  • Eckhard Mandelkow
  • Thomas Dyrks
  • Sabine Krause
  • Justin W Torpey
  • Barbara A Cottrell
  • Sebastian Jaeger
  • Marcus Pickhardt
  • Anne M Martin
  • Andrea Schweitzer
  • Sabine Paul
  • Cornelia Dorner-Ciossek
  • Anna Schneider
  • Mathias Jucker
  • Rebecca Berdeaux
  • Markus P Kummer
  • Nicole Teusch
  • Tawnya E Smith
  • Kevin W Jessing
  • Kenton H Zavitz
  • D C McLendon
  • Victor V Ozols
  • Jason Eriksen

Detail Information

Publications17

  1. ncbi request reprint Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds
    Eva Czirr
    Emmy Noether Research Group, Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg University Mainz, Mainz, Germany
    Neurodegener Dis 3:298-304. 2006
    ..Current efforts to improve the pharmacological shortcomings of available gamma-secretase modulators will hopefully lead to the development of clinically useful Abeta42-lowering compounds in the near future...
  2. ncbi request reprint NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?
    Sascha Weggen
    Molecular Neuropathology Group, Department of Neuropathology, Heinrich Heine University, D 40225 Dusseldorf, Germany
    Trends Pharmacol Sci 28:536-43. 2007
    ....
  3. pmc LRP1 is critical for the surface distribution and internalization of the NR2B NMDA receptor subtype
    Wladislaw Maier
    University Medical Center of the Johannes Gutenberg University of Mainz Institute of Pathobiochemistry, Duesbergweg 6, Mainz 55099, Germany
    Mol Neurodegener 8:25. 2013
    ..Moreover, mice harboring a conditional neuronal knock-out mutation of the entire Lrp1 gene display NMDA-associated behavioral changes. However, the exact role of LRP1 on NMDA receptor function remains still elusive...
  4. pmc Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease
    Sascha Weggen
    Department of Neuropathology, Heinrich Heine University, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    Alzheimers Res Ther 4:9. 2012
    ....
  5. ncbi request reprint Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening
    Heiko Zettl
    Department of Neuropathology, Heinrich Heine University, D 40225 Duesseldorf, Germany
    ACS Chem Biol 7:1488-95. 2012
    ..We describe the identification of a series of 4-hydroxypyridin-2-one derivatives, which display a novel type of γ-secretase modulation with equipotent inhibition of Aβ42 and Aβ38 peptide species...
  6. doi request reprint Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase
    Eva Czirr
    Molecular Neuropathology Group, Department of Neuropathology, Heinrich Heine University, D 40225 Duesseldorf, Germany
    J Biol Chem 283:17049-54. 2008
    ..These data provide evidence that Abeta42 and Abeta38 species can be independently generated by gamma-secretase and argue against a precursor-product relationship between these peptides...
  7. doi request reprint Nonsteroidal anti-inflammatory drugs and ectodomain shedding of the amyloid precursor protein
    Stefanie Leuchtenberger
    Department of Neuropathology, Heinrich Heine University, Dusseldorf, Germany
    Neurodegener Dis 6:1-8. 2009
    ....
  8. ncbi request reprint Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations
    Eva Czirr
    Emmy Noether Research Group, Mainz, Germany
    J Biol Chem 282:24504-13. 2007
    ....
  9. ncbi request reprint Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond
    Stefanie Leuchtenberger
    Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
    Curr Pharm Des 12:4337-55. 2006
    ..Hopes are high that in the near future this will lead to the development of clinically viable compounds which selectively target Abeta42 as a key molecule in the pathogenesis of AD...
  10. ncbi request reprint Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production
    Thomas Kukar
    Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    Nat Med 11:545-50. 2005
    ....
  11. pmc NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo
    Jason L Eriksen
    Department of Neuroscience, Mayo Graduate School, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA
    J Clin Invest 112:440-9. 2003
    ..Because R-flurbiprofen reduces Abeta42 levels by targeting gamma-secretase and has reduced side effects related to inhibition of cyclooxygenase (COX), it is an excellent candidate for clinical testing as an Abeta42 lowering agent...
  12. ncbi request reprint Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42
    Stefanie Leuchtenberger
    Emmy Noether Research Group, Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg University Mainz, Mainz, Germany
    J Neurochem 96:355-65. 2006
    ..Taken together, these results seem to exclude a mechanistic involvement of ROCK in the Abeta42-lowering activity of NSAIDs...
  13. ncbi request reprint Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease?
    Rajeshwar Narlawar
    Clemens Schöpf Institute of Chemistry and Biochemistry, Darmstadt University of Technology, Petersenstrasse 22, 64287 Darmstadt, Germany
    ChemMedChem 3:165-72. 2008
    ..Additionally, several compounds are potent inhibitors of tau protein aggregation and depolymerized tau protein aggregates at low micromolar concentrations...
  14. doi request reprint LRP1 modulates APP trafficking along early compartments of the secretory pathway
    Elaine Waldron
    Institute of Physiological Chemistry and Pathobiochemistry, Molecular Neurodegeneration, Johannes Gutenberg University Mainz, 55099 Mainz, Germany
    Neurobiol Dis 31:188-97. 2008
    ..In addition, we provide evidence that APP metabolism occurs in close conjunction with LRP1 trafficking, highlighting a new role of lipoprotein receptors in neurodegenerative diseases...
  15. ncbi request reprint Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity
    Sascha Weggen
    Department of Neurosciences, University of California San Diego, La Jolla, California 92093, USA
    J Biol Chem 278:31831-7. 2003
    ..In sum, these results strongly suggest that NSAIDs represent a founding group of compounds that lower A beta 42 production by direct modulation of gamma-secretase activity or its substrate...
  16. ncbi request reprint The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production
    Sarah A Sagi
    Department of Neurosciences, University of California San Diego, La Jolla, California 921093, USA
    J Biol Chem 278:31825-30. 2003
    ..Thus, NSAIDs do not appear to alter A beta 42 production indirectly through previously identified cellular targets and may interact directly with the gamma-secretase complex itself to affect amyloid production...
  17. ncbi request reprint Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain
    Sascha Weggen
    Department of Neurosciences, University of California San Diego, La Jolla, California 92093, USA
    J Biol Chem 278:30748-54. 2003
    ....